PetaOmics., Inc. is a life sciences firm focused on functional genomics, epigenomics, and DNA methylation sequencing. The company is developing innovative approaches that facilitate the epigenetic analysis of human cells, which are applicable to all human cell types. The company will commercialize reagent kits designed to enable ground-breaking experiments in genomics and epigenomics. Some of the new research approaches enabled by PetaOmics' kits and related technologies will facilitate the study, from an epigenetic standpoint, of chronic, complex diseases such as autoimmunity and the metabolic syndrome. Information generated using PetaOmics technologies will be of value for biomedical research, pharmaceutical drug discovery, and development of diagnostic tests. Prior to founding PetaOmics, Dr. Paul Lizardi was a Professor of Pathology at Yale University. He is the primary inventor named on 25 issued patents which collectively have been licensed to over 80 commercial entities. In the year 2006 Dr. Lizardi was named by the Journal Nature Biotechnology in their short list of the 75 most influential scientists in life science technology development.
